4//SEC Filing
ZANTE GREG 4
Accession 0001193125-25-254298
CIK 0001607678other
Filed
Oct 27, 8:00 PM ET
Accepted
Oct 28, 7:47 PM ET
Size
7.2 KB
Accession
0001193125-25-254298
Insider Transaction Report
Form 4
ZANTE GREG
Chief Financial Officer
Transactions
- Sale
Common Stock, par value $0.00001 per share
2025-10-28$35.00/sh−6,185$216,481→ 173,592 total - Award
Common Stock, par value $0.00001 per share
2025-10-27+11,117→ 179,777 total
Footnotes (3)
- [F1]The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2025, 33.33% of which vested on October 27, 2025 upon the achievement of a non-financial performance goal and 15% of which vested also on October 27, 2025 upon the partial achievement of a non-financial performance goal.
- [F2]These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.6525 to $35.3939, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote.
Documents
Issuer
Viking Therapeutics, Inc.
CIK 0001607678
Entity typeother
Related Parties
1- filerCIK 0001264949
Filing Metadata
- Form type
- 4
- Filed
- Oct 27, 8:00 PM ET
- Accepted
- Oct 28, 7:47 PM ET
- Size
- 7.2 KB